Simcere to Market Four Amgen Biosimilars in China

03:05 EDT 28 Sep 2017 | ChinaBio Today

Simcere Pharmaceutical of Nanjing struck a deal with Amgen to co-develop and commercialize four Amgen biosimilars in China. The exact biosimilars were not disclosed, though Amgen said they address needs in inflammation and oncology. Earlier this month, Amgen was approved by the FDA to market a biosimilar to Roche's Avastin, the first oncology biosimilar approved in the US. Amgen has disclosed a portfolio of six biosimilars and says it has three more in earlier development. More details....

Stock Symbol: (NSDQ: AMGN)

Share this with colleagues:

Original Article: Simcere to Market Four Amgen Biosimilars in China


More From BioPortfolio on "Simcere to Market Four Amgen Biosimilars in China"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...